课题基金 / 基金详情

Validation and qualification of a multiplex hypoxia biomarker for radiotherapy individualisation

Validation and qualification of a multiplex hypoxia biomarker for radiotherapy individualisation
用于放射治疗个体化的多重缺氧生物标志物的验证和鉴定
批准号:
G0801525/1
负责人:
Catharine West
金额:
$89.6万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2009
资助国家:
英国
项目状态:
已结题
起止时间:
2009 至 --

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
这项研究的背景是什么?在英国,每年大约有30万患者患上癌症,大约50%的患者在治疗过程中的某个时候会接受放疗。缺氧(什么意思?肿瘤中的低氧与放射治疗的耐药性有关。如果医生能够确定肿瘤是否缺氧,这将有助于他们改善治疗方法,为患者提供最佳的治愈机会。这项研究想要达到什么目的?先前的研究发现了一组与头颈部肿瘤缺氧有关的99个基因。最近,这一群体被细化为一个仅包含30个基因的子集。本研究旨在证实减少的30基因组是否可以用于临床作为缺氧的检测。为了做到这一点,我们将使用从选择参加临床试验的患者身上收集的肿瘤样本。我们知道在这30个基因中有一种特殊的活动模式,它反映了肿瘤中的氧气水平。我们正在研究识别这种模式的不同方法,以找到最可靠和可重复的方法,从而在临床中最有用。我们还想研究我们的30个基因模式是否可以识别和预测其他癌症(如膀胱癌)的缺氧。我们将研究每种癌症类型是否需要不同的30个基因组。为什么这很重要?如果我们能够开发出一种可靠的缺氧测试方法,我们就可以在临床试验中进行试验。如果成功的话,它可以被引入临床实践。这将意味着患者将接受最适合他们的治疗,这将改善结果。考虑到每年有大量的癌症患者接受放射治疗,这将对英国的癌症生存率有显著的好处。如何以及在哪里进行研究?这项研究建立在来自英国和欧盟的科学家和医生之间长期合作的基础上。它将由曼彻斯特大学的凯瑟琳·韦斯特博士领导,她在测量患者肿瘤缺氧方面有多年的经验。这项研究将使用从患者那里收集的肿瘤样本,这些患者完全知情地同意将其组织用于未来经伦理批准的研究中。
英文摘要
What is the background of this research?Approximately 300,000 patients develop cancer in the UK each year, and around 50% will undergo radiotherapy at some point during treatment. Hypoxia (meaning ?low oxygen?) in a tumour is associated with resistance to radiotherapy. If doctors could identify whether a tumour was hypoxic, it would help them improve treatment to give the best chance of cure for a patient.What is the research trying to achieve?Previous research identified a group of 99 genes that are linked with hypoxia in head and neck tumours. More recently this group has been refined to a subset that comprises just 30 genes. This research aims to confirm whether the reduced 30-gene group can be used in the clinic as a test for hypoxia. To do this, we will be using tumour samples collected from patients who chose to take part in a clinical trial. We know there is a special pattern of activity in these 30 genes that reflects oxygen levels in a tumour. We are investigating different ways of identifying this pattern to find the one which is most reliable and reproducible, and therefore most useful in the clinic.We also want to investigate whether our pattern of 30 genes can identify and predict hypoxia in other cancers e.g. bladder. We will investigate whether a different 30-gene group is needed for each cancer type.Why is this important?If we are able to develop a reliable test for hypoxia, we could try it out in a clinical trial. If successful it could be introduced into clinical practice. This would mean patients would receive the treatment that is best for them, which would improve outcome. Given the large number of cancer patients who undergo radiotherapy each year, this would have a significant benefit on cancer survival in the UK.How and where is the research to be conducted?This study builds on long-standing collaborations between scientists and doctors from across the UK and EU. It will be led by Dr. Catharine West at the University of Manchester, who has many years experience of measuring tumour hypoxia in patients. This study will use tumour samples collected from patients who gave full and informed consent for their tissue to be used in future ethically approved research.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金